Please log in to determine if you are eligible to purchase PT Programs.
HLA DISEASE ASSOCIATION-DRUG RISK - DADR2
DADR2
Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

Analyte Challenges per Shipment Number of Shipments
HLA-A*29:01 3 Two shipments per year
HLA-A*29:02 3
HLA-DQA1*04:01 3
HLA-DQA1*05:01 3
HLA-DQB1*03:02 3
HLA-DQB1*06:02 3
HLA-DRB1*03:01 3
HLA-DRB1*03:02 3
HLA-DRB1*04:02 3
HLA-DRB1*04:03 3
HLA-DRB1*04:06 3
HLA-DRB1*08:02 3
HLA-DRB1*08:04 3
HLA-DRB1*14:04 3
HLA-DRB1*14:05 3
HLA-DRB1*14:08 3
HLA-DRB1*15:01 3
HLA-DRB1*15:02 3
DQA1*02 3
DQA1*03 3
DQA1*05 3
DQB1*02:01 3
DQB1*02:02 3

Additional Information

  • This Survey will challenge the laboratory to accurately identify the presence or absence of alleles associated with a variety of disease states (listed below) and/or the adverse reactions to specific drugs.

    • Celiac disease (CD)
    • Narcolepsy (N)
    • Pemphigus Vulgaris (PV)
    • Psoriasis (P)
    • Antiglomerular basement membrane disease (ABM)
    • Birdshot retinochoroidopathy (BR)
    • Idiopathic myopathy (IM)

Program Information

  • Three 0.1‑mL specimens, each containing 200 µg/mL of human DNA in media

Shipping Schedule

  • Shipment A: April 16
  • Shipment B: August 27